ArticleJCO clinical cancer informatics2025
Risk Score Model of Aging-Related Genes for Bladder Cancer and Its Application in Clinical Prognosis.
Article in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBladder cancer (BLCA) ranks as the tenth most common malignancy worldwide, with rising incidence and mortality rates. Owing to its molecular and clinical heterogeneity, BLCA is associated with high rates of recurrence and metastasis after surgery, contributing to a poor 5-year survival rate. There is a pressing need for highly sensitive and specific molecular biomarkers to enable early identification of high-risk patients, guide clinical management, and improve patient outcomes. This study aimed to develop a prognostic model on the basis of aging-related genes (ARGs) to evaluate survival outcomes and immunotherapy responsiveness in patients with BLCA, and to further explore its relevance to the tumor immune microenvironment and drug sensitivity. MATERIALS AND
methodsTranscriptomic and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus were used to construct a 12-gene ARG-based prognostic signature through LASSO and Cox regression analyses. Patients were stratified into high-risk and low-risk groups according to the median risk score. Kaplan-Meier survival curves, receiver operating characteristic analyses, and nomograms were used to assess the predictive value of the model. Univariate and multivariate Cox regression analyses were conducted to determine its prognostic independence.
resultsTwelve ARGs were identified. Patients in the low-risk group exhibited significantly better overall survival (
conclusionThe ARG-based risk score independently predicts clinical prognosis in BLCA and correlates with immune microenvironment characteristics, offering potential value in guiding personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.